

# Quality use of medicines in Australia

Professor Libby Roughead



University of  
South Australia


# Today's talk

- Some history:
  - How did quality use of medicines start and what does it mean?
- Building
  - What have we built and achieved?
- Where are we now?
  - What are the next set of challenges?




# The beginning: QUM was driven by consumers

- In the late 1980s the Consumer Movement published three seminal documents.
  - “Too much of a good thing”
  - “Developing a rational medicinal drug policy for Australia - What does it mean?”
  - “Towards a National Medicinal Drug Policy”
- In 1991 the Australian Health Minister responded, establishing
  - an expert advisory committee to develop the national strategy for achieving quality use of medicines and
  - a national representative committee to advise on the national medicines policy



# The result: the national strategy for quality use of medicines

- Four key developments laid the groundwork for what would be a cultural shift in the way Australia thought about medicine use.
  - A definition of quality use of medicines that extended beyond the medicine
  - Principles of working that included; the primacy of the consumer, partnership, multi-disciplinary, consultative, collaborative activity, and systems based approaches
  - A vision grounded in behavioural theory to achieve the outcome
  - Indicators to evaluate progress



# The importance of the definition


- This definition shifted the way we thought about medicine use
- For the first time we had a definition of quality use of medicines that went beyond the medicine
  - Judicious selection of management options
  - Where a medicine was necessary, appropriate selection of medicines
  - Safe and effective use of medicines




# The importance of the behavioural underpinning




## How do individuals learn?




## How do individuals learn over time?




## How do communities learn or change over time?



## How do communities learn or change?



# Delivery of the intervention program within the theoretical frameworks





**All partners**


**Adopting the principles,**

**Implementing the building blocks,**

**Across all stages of behaviour change,**

**Across all settings of the health system,**

**Enables quality use of medicines**



This vision, which would now be described as co-design and theory informed was realized 15 years before the first academic papers citing this as the way forward



- At the time the quality use of medicines vision was created, Australia had limited resources to support quality use of medicines
  - Antibiotic guidelines,
  - Australian Prescriber,
  - The Adverse Drug Reaction Advisory Committee Bulletin, and
  - Approved Product Information



The 1990's was the era of building



We were gaining understandings



**hospitals**

**and the quality**



**use of medicines**



# We were building new ways of practice



RESEARCH



DOMICILIARY MEDICATION MANAGEMENT  
HOME MEDICINES REVIEW

HELPING YOUR PATIENTS MANAGE THEIR MEDICINES AT HOME

**Developing and evaluating a model for pharmaceutical care in Australian community pharmacies**

GEOFF MARCH, ANDREW GILBERT, ELIZABETH ROUGHHEAD and NEIL QUINTRELL

**Objective** — To develop and evaluate a medication management service. The service was based on the principles of pharmaceutical care and targeted patients at risk of medication misadventure, primarily elderly patients in community pharmacies.

**Methods** — In phase one, pharmacists defined the service in a patient care process, systematic documentation and targeted complementary relationship with services of the service. In phase two, the service was provided over an 11-month period and evaluation of the service was undertaken.

**Key findings** — Of the patients surveyed, 74% had more than one or more medication problems. Of the patients surveyed, 74% had more than one or more medication problems. Of the patients surveyed, 74% had more than one or more medication problems.

## Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs

Frank W May, Debra S Rowett, Andrew L Gilbert, Janet I McNeece and Eve Hurley


### Abstract

**Objective:** Exploration of longer-term outcomes of an ongoing educational-outreach service for community doctors.

**Design:** Quasi-experimental, with parallel and historical comparisons.

Face-to-face communication and academic detailing have been shown to have a positive influence on prescribing behaviour of medical practitioners.<sup>1-7</sup> Uncertainty remains about the duration of effects, the time of

# We were developing resources




**NPS**  
National Prescribing Service Limited

### Audit of provision of over-the-counter NSAIDs

**Using this form** This form can be used by graduate/trainee pharmacists and non-pharmacist staff as well as by the pharmacist. It acts as a guide to the information that should be used to appropriately advise on OTC NSAID use for adults. Tick all applicable boxes to indicate answers.  
**NB** If the customer's answers result in a tick in any box with a heavy red border , graduate/trainee pharmacists and non-pharmacist staff should refer the customer to the pharmacist for advice.



Auditing the request	Therapeutic notes from guidelines <sup>3,4</sup>
<b>Did the customer ...</b> make a direct request for an NSAID? <input type="checkbox"/> present with a symptom-based request for which you considered an NSAID? <input type="checkbox"/>	assess symptoms
<b>Who is the patient?</b> <ul style="list-style-type: none"> <li>adult 13-65 years <input type="checkbox"/></li> <li>older adult &gt;65 years <input type="checkbox"/></li> <li>customer not asked <input type="checkbox"/></li> </ul>	NSAIDs ↑ risk gastrointestinal (GI) ulceration & renal impairment
<b>What are the symptoms?</b> <ul style="list-style-type: none"> <li>fever <input type="checkbox"/></li> <li>headache <input type="checkbox"/></li> <li>migraine <input type="checkbox"/></li> <li>dysmenorrhoea (period pain) <input type="checkbox"/></li> <li>dental pain <input type="checkbox"/></li> <li>sinus pain <input type="checkbox"/></li> <li>backache, hip pain <input type="checkbox"/></li> <li>strains and sprains <input type="checkbox"/></li> <li>acute gout <input type="checkbox"/></li> <li>osteoarthritis <input type="checkbox"/></li> <li>tendonitis <input type="checkbox"/></li> <li>other <input type="checkbox"/></li> <li>rheumatoid arthritis <input type="checkbox"/></li> <li>customer not asked <input type="checkbox"/></li> </ul>	paracetamol recommended paracetamol or aspirin usually recommended soluble aspirin, soluble paracetamol or NSAID recommended NSAID recommended aspirin*, paracetamol or NSAID* recommended (*caution - anti-platelet action in extraction), refer to dentist use paracetamol plus oral or topical decongestant paracetamol preferred or NSAID RICE (rest, ice, compression, elevation) recommended NSAID recommended paracetamol recommended paracetamol recommended
<b>How long have symptoms been present?</b> <ul style="list-style-type: none"> <li>&lt; 2 days <input type="checkbox"/></li> <li>2 days or more, or recurrent <input type="checkbox"/></li> <li>customer not asked <input type="checkbox"/></li> </ul>	assess symptoms, consider referral to doctor
<b>What treatment or other action has already been taken?</b> <ul style="list-style-type: none"> <li>no other treatment tried <input type="checkbox"/></li> <li>non-drug therapy, eg RICE, relaxation, steam inhalation, physiotherapy, etc <input type="checkbox"/></li> <li>has not used an NSAID before <input type="checkbox"/></li> <li>NSAID used previously <input type="checkbox"/></li> <li style="padding-left: 20px;">aspirin <input type="checkbox"/></li> <li style="padding-left: 20px;">paracetamol <input type="checkbox"/></li> <li>other analgesia, eg NSAID gels, rubs <input type="checkbox"/></li> <li>combination analgesics eg Mersyndol® <input type="checkbox"/></li> <li>complementary, eg herbal medicines, homoeopathy, natural therapy <input type="checkbox"/></li> <li>customer not asked <input type="checkbox"/></li> </ul>	assess symptoms, consider referral to doctor check drug used, efficacy, dose, frequency appropriate check efficacy, dose, frequency appropriate check efficacy, dose, frequency appropriate check efficacy, dose, frequency appropriate check efficacy
<b>How effective was any previous treatment?</b>	




## DRUG Indicators

MANUAL OF  
CLINICAL INDICATORS OF THE  
QUALITY USE OF MEDICATIONS (QUM)  
BY NURSES

# We were developing standards



By 2003



By 2004, Australia had established nearly all of the resources we thought we needed to facilitate quality use of medicines



# The 2000's – enabling and sustaining

- The next 15 years saw a focus on building a skilled workforce and increasing participation
- NPS Medicine Wise expanded and medicine review services expanded
- 2018 -19
  - 31,000 academic detailing visits
  - 3,500 doctors undertook case studies
  - 95% of all medical schools using the national prescribing curricula
  - 150,000 people receiving medicine reviews
  - 18 million visits to the NPS Medicine Wise, formerly National Prescribing Service, website
- Organisations representing primary care practitioners have all endorsed the QUM approach
  - AMA
  - RACGP
  - PSA
  - Guild
  - RCNA
  - Clinical Pharmacology
- Included in their training or professional standards




# So where are we now?

- In 2022 a decision was made to restructure the way some quality use of medicines programs were funded and delivered
- It comes at a time when new challenges are emerging
- It is also 20 years since the last renewal of the national strategy
- So the change offers the opportunity for both reflection and renewal
  - To consider how we might be best placed to meet the new challenges to support quality use of medicines



# The 21<sup>st</sup> century challenges for health and medicines

- Populations are ageing
- Multiple illnesses are more common
- Multiple health practitioners are involved in care
- New medicines are most commonly used in conjunction with existing treatments
- New understandings of genetic and metabolic systems are changing our understanding of medicine effects
- New understandings of neuroscience are changing our understanding of the role of non-pharmacological options
- Our clinical trial system and our health system have not yet fully adapted to these changes
- Digital technologies, social media and artificial intelligence are changing the way we interact, gather knowledge, communicate.




# Challenge 1: Multi-morbidity and polypharmacy

- We've got older
- And along with that we live longer with more illnesses
  - The prevalence of multiple chronic illnesses in Australia rose four-fold between 1985 and 2005
- And we treat illnesses more intensively
  - Up until 1998 all guidelines recommended a single treatment for a disease; if a treatment didn't work, we switched
  - 1998 first recommendations globally for diabetes add on therapy
  - 2000 first recommendations globally for add on therapy in hypertension




# The 2020s – the era of polypharmacy

UK – people on five or more medicines



[10.1186/s12916-015-0322-7](https://doi.org/10.1186/s12916-015-0322-7)


USA – people on five or more medicines




[DOI:10.1371/journal.pone.0118991](https://doi.org/10.1371/journal.pone.0118991)

Polypharmacy regimens interact.

13.7 alerts per 10 medicines



# Guidelines don't always assist in helping us when it comes to multi-morbidity



UK study

- 133 serious medicine – medicine interactions for medicines recommended in the type 2 diabetes guideline and guidelines for 11 other conditions

• DOI: [10.1136/bmj.h949](https://doi.org/10.1136/bmj.h949)



University of  
South Australia

# Challenge 2: using medicines is harder

- the types of medicines we use are more complex, more costly and frequently specialist prescribed



INJECTION



## ASTHMA & COPD MEDICATIONS

SABA RELIEVERS	ICS PREVENTERS	ICS/LABA COMBINATIONS	LAMA MEDICATIONS
<b>Ventolin Inhaler</b> † <sup>▲</sup> salbutamol 100mcg  <b>Bricanyl Turbuhaler</b> † <sup>▲</sup> <sup>●</sup> terbutaline 500mcg	<b>Asmol Inhaler</b> † <sup>▲</sup> salbutamol 100mcg  <b>Airomir Autohaler</b> † <sup>▲</sup> <sup>●</sup> salbutamol 100mcg	<b>Flixotide Inhaler</b> † fluticasone propionate 50mcg* + 120mcg + 250mcg *Flixotide Juniper  <b>Fluticasone Cipla Inhaler</b> † fluticasone propionate 125mcg + 250mcg  <b>Fluticasone + Salmeterol Cipla Inhaler</b> † fluticasone propionate/salmeterol 125/25 + 250/25 †  <b>Seretide MDI</b> † <sup>▲</sup> fluticasone propionate/salmeterol 50/25 + 125/25 + 250/25 †  <b>Seretide Accuhaler</b> † <sup>▲</sup> fluticasone propionate/salmeterol 50/25 + 250/25 + 500/25 †  <b>Flutiform Inhaler</b> † <sup>▲</sup> fluticasone propionate/formoterol 50/5 + 120/5 + 250/10	<b>Spiriva Respimat</b> † <sup>▲</sup> <sup>●</sup> tiotropium 2.5mcg  <b>Spiriva Handihaler</b> † <sup>▲</sup> tiotropium 18mcg  <b>Braltus Zonda</b> † <sup>▲</sup> tiotropium 10mcg  <b>Bretaris Genuair</b> † <sup>▲</sup> aclidinium 32mcg  <b>Seebri Breezhaler</b> † <sup>▲</sup> glycopyrronium 50mcg  <b>Increase Ellipta</b> † <sup>▲</sup> umeclidinium 62.5mcg
RESOURCES	SAMA MEDICATION	NON STEROIDAL PREVENTER	LAMA/LABA COMBINATIONS
<b>TREATMENT GUIDELINES</b> Australian Asthma Handbook: <a href="http://astmahandbook.org.au">astmahandbook.org.au</a>  <b>COPD-X Plan:</b> <a href="http://copdx.org.au">copdx.org.au</a>  <b>INHALER TECHNIQUE</b> How-to videos, patient and practitioner information <a href="http://nationalasthma.org.au">nationalasthma.org.au</a> Inhalers/MDIs should be used with a compatible spacer  <b>HOW-TO VIDEOS</b> 	<b>Atrovent Metered Aerosol</b> † <sup>▲</sup> ipratropium 21mcg  <b>Pulmicort Turbuhaler</b> † budesonide 100mcg + 200mcg + 400mcg  <b>QVAR Autohaler</b> † budesonide 50mcg + 100mcg  <b>QVAR Autohaler</b> † budesonide 50mcg + 100mcg	<b>Montelukast Tablet</b> † <sup>▲</sup> montelukast 4mg + 5mg + 10mg Generic medicine suppliers  <b>Alvesco Inhaler</b> † ciclesonide 80mcg + 160mcg  <b>Arnuity Ellipta</b> † fluticasone furoate 50mcg + 100mcg + 200mcg	<b>Symbicort Turbuhaler</b> † <sup>▲</sup> budesonide/formoterol 100/6 + 200/6 + 400/12 †  <b>DuoResp Spiromax</b> † <sup>▲</sup> budesonide/formoterol 200/6 + 400/12 †  <b>Symbicort Rapihaler</b> † <sup>▲</sup> budesonide/formoterol 50/2 + 100/2 + 200/4 †  <b>Breo Ellipta</b> † <sup>▲</sup> fluticasone furoate/vilanterol 100/25 + 200/25  <b>Spiolto Respimat</b> † <sup>▲</sup> tiotropium/budaterol 2.5/2.5  <b>Brimica Genuair</b> † <sup>▲</sup> aclidinium/formoterol 360/7  <b>Spiolto Respimat</b> † <sup>▲</sup> tiotropium/budaterol 2.5/2.5  <b>Anoro Ellipta</b> † <sup>▲</sup> umeclidinium/vilanterol 42.5/25  <b>Trelegy Ellipta</b> † <sup>▲</sup> fluticasone furoate/umeclidinium/vilanterol 100/62.5/25mcg all units in mcg
LABA MEDICATIONS	<b>LABA MEDICATIONS</b> <b>Oxis Turbuhaler</b> † formoterol 50mcg + 100mcg  <b>Serevent Accuhaler</b> † salmeterol 50mcg  <b>Onbrez Breezhaler</b> † <sup>▲</sup> indacaterol 100mcg + 300mcg  <b>Fostair Inhaler</b> † <sup>▲</sup> beclomethasone/formoterol 50/6 all units in mcg  <b>Utibro Breezhaler</b> † <sup>▲</sup> indacaterol/glycopyrronium 110/50 all units in mcg  <b>Anoro Ellipta</b> † <sup>▲</sup> umeclidinium/vilanterol 42.5/25 all units in mcg  <b>Trelegy Ellipta</b> † <sup>▲</sup> fluticasone furoate/umeclidinium/vilanterol 100/62.5/25mcg all units in mcg		


This chart was developed independently by the National Asthma Council Australia with support from Mylan Health, Chiesi Australia, GSK Australia & AstraZeneca Australia. 2020 © National Asthma Council Australia. PBS PRESCRIBERS † Asthma unrestricted benefit ‡ Asthma restricted benefit ▲ Asthma authority required ● COPD unrestricted benefit # COPD restricted benefit † COPD authority required. Check TGA and PBS for current age and condition criteria.






# What did medicine use look like when we started

- Cardiovascular, alimentary, respiratory, central nervous system and anti-infectives accounted for the majority of use
  - Not surprisingly, the QUM focus was getting GPs involved in QUM





- While the same medicine classes still account for the majority of use, antineoplastic & immunomodulatory medicine use has risen 13 fold
- And now accounts for 40% of all PBS costs
- And so we need to consider how we engage specialists in quality use of medicines


Source: PBS group reports 2024



University of  
South Australia

## Challenge number 3: We're caring for more vulnerable people at home

- Major shift since the original strategy is the move to care in the home
  - Hospital in the home
  - Age care support
  - Disability and mental health support
- We don't have a lot of insight into how well supported these groups but we know there are lots of barriers



# Challenge 4: grabbing the opportunities with changing service delivery

- Expanded prescribing
  - Pharmacist antibiotic prescribing in Urinary Tract Infections
  - Nurse Practitioner
- New models of practice
  - Pharmacists in general practice
  - Pharmacists in aged-care
  - Pharmacist vaccination
  - Virtual models of care
- State QUM programs
  - 24 hour pharmacy funding
  - State funded Medicine Reviews
- New opportunities in digital health
  - Automation
  - Digital biomarkers
  - Precision decision support
- New understandings from systems sciences
  - Rethink the therapeutic continuum from the biological to the social



# Renewal going forward

- Consumer led – consumer driven actions underpinned the original policy
  - Many consumer led activities, such as medicines information people, medicines talk, are no longer happening
  - Consideration of how to re-engage a consumer driven QUM movement is required, particularly in culturally and ethnically diverse communities.
- Dialogue, collaboration, facilitation and coordination
  - More groups than ever before now responsible for quality use of medicines; mechanisms to address emerging issues outside of the remit of organizations or institutions still required
- Need to engage medical specialists in QUM



# Renewal going forward

- Need more effective structures, mechanisms and resources to support management of multi-morbidity
- De-prescribing has emerged as one focus in response to the rise of multi-morbidity and polypharmacy
  - Many tools and resources developed
  - Not yet integrated into routine practice
  - Not integrated into other sources of objective information
    - Eg Product information



# Renewal going forward

- Digital health initiatives have brought new stakeholder groups to the table and there is urgent work to engage and communicate across groups for mutual understanding of quality use of medicines, both definition and ways of working.
- We also need to consider how digital tools, artificial intelligence and social media might be harnessed in a positive manner, and how we monitor and avoid the negative impact that can contribute to over-diagnosis, unnecessary care or avoidance of needed care.



# Conclusion

- The original policy vision, driven by consumers, emboldened us to achieve quality use of medicines. Its processes for working together still hold true
  - Consumer centred
    - Co-designed
    - Activities arising from lived experience
  - Theory informed
  - Multidisciplinary, consultative and collaborative
  - Systems based
- We need to consider how to recapture this vision to gain new understandings, develop new models of practice, resources and standards and respond to the challenges of the 21st century

